Researchers evaluated the frequency of lectin-type oxidized LDL receptor 1 (LOX-1+) polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in NSCLC patients treated with nivolumab. This evidence concerns the gene OLR1 and non-small cell lung carcinoma.